ARTV
Artiva Biotherapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$9.15-6.25%
Price as of Jul 20, 2026
ARTV growth
Artiva Biotherapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -19.5%
- EBIT
- -22.8%
- EPS
- -11.3%
- Free cash flow
- -31.6%
- Operating cash flow
- -30.2%
Forward estimates
- Revenue
- —
- EBITDA
- +58.6%
- EPS
- +11.2%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -45.0%
- EBIT
- -34.7%
- Net income
- -43.4%
- EPS
- +34.0%
- Free cash flow
- -42.5%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.